(Q37886156)

English

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation

scientific article published on June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation (English)

1 reference

Europe PubMed Central

24 August 2017

1 reference

ChEBI release 2020-05-28

Michael Camilleri

2

object named as

Michael Camilleri

1 reference

Europe PubMed Central

24 August 2017

author name string

Maria Vazquez Roque

1

1 reference

Europe PubMed Central

24 August 2017

publication date

1 June 2011

1 reference

Europe PubMed Central

24 August 2017

Expert Review of Gastroenterology & Hepatology

1 reference

Europe PubMed Central

24 August 2017

5

1 reference

Europe PubMed Central

24 August 2017

3

1 reference

Europe PubMed Central

24 August 2017

301-310

1 reference

Europe PubMed Central

24 August 2017

Epidemiology of constipation in North America: a systematic review

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Cumulative incidence of chronic constipation: a population-based study 1988-2003.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Physician visits in the United States for constipation: 1958 to 1986.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

The serotonin signaling system: from basic understanding to drug development for functional GI disorders

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

A placebo-controlled trial of prucalopride for severe chronic constipation

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Prucalopride, a systemic enterokinetic, for the treatment of constipation

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Linaclotide - a secretagogue and antihyperalgesic agent - what next?

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Pilot study on the effect of linaclotide in patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Efficacy of linaclotide for patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.30

21 January 2018

Identifiers

10.1586/EGH.11.30

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37886156&oldid=2093747039"